Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognition in Healthy Individuals. (BluLife)

May 18, 2021 updated by: Dr Ana Rodriguez-Mateos, King's College London

Randomised, Double-blind, Placebo Controlled, Crossover Trial Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognitive Performance in Healthy Individuals Across the Life Course.

This study aims to determine the effect of blueberry (poly)phenol vs placebo on vascular function and cognitive performance with an insight into cerebral blood flow velocity changes, across all ages of the general healthy population.

Study Overview

Status

Completed

Conditions

Detailed Description

Foods rich in certain (poly)phenols, particularly flavonoids, such as berries, have been shown to improve measures of vascular function as well as cognitive performance in human intervention studies. Blueberries are rich in anthocyanins, a subclass of flavonoids that have been widely linked to health benefits, particularly improvements in endothelial function. Research have previously shown that blueberries improve executive functioning and memory in both healthy adults and children. These improvements were seen within 2-5 hours post-consumption of blueberries, a time-course that positively correlates with improvements in vascular function (measured as flow-mediated dilation). This indicates that increases in blood flow may influence improvements in cognitive performance. To date no study has investigated whether blueberry consumption can induce an increase in cerebral blood flow, with subsequent improvements in vascular and cognitive function. In this study, investigators aim to directly link wild blueberry consumption with increased vascular and cerebral blood flow and positive cognitive outcomes in healthy individuals through the life course, between the ages of 8 and 80 years old. Investigators will use a large group of healthy subjects representative of the general public over a wide age range in males and females to evaluate the generalisability of the health benefits of blueberry consumption.

Study Type

Interventional

Enrollment (Actual)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • London, United Kingdom, SE1 9NH
        • King's College London

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 80 years (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Healthy men and women aged 8-80 years old
  • Are able to understand the nature of the study
  • Able and willing to give signed written informed consent with the addition of a parent/carer for the consent of children under 16.
  • Are willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study.

Exclusion Criteria:

  • Manifest cardiovascular diseases including coronary artery disease, cerebrovascular disease and peripheral artery disease.
  • Hypertensive, as defined as SBP superior or equal to 140 mmHg or DBP superior or equal to 90 mmHg.
  • Obese participants, defined as BMI superior or equal to 30.
  • Diabetes mellitus and metabolic syndrome.
  • Acute inflammation, terminal renal failure or malignancies.
  • Abnormal heart rhythm (lower or higher than 60-100 bpm).
  • Allergies to berries or another significant food allergy.
  • Subjects under medication or on vitamin/dietary supplements (within 2 weeks of baseline).
  • Subjects who have lost more than 10% of their weight in the past 6 months or are currently on a diet.
  • Subjects who reported participant in another study within one month before the study starts.
  • Subjects who smoke cigarettes.
  • MCI or dyslexic or unable to complete the cognitive function tasks for any reason such as visual impairments.
  • Subjects who require chronic antimicrobial or antiviral treatment.
  • Subjects with unstable psychological condition.
  • Subjects with history of cancer, myocardial infarction, cerebrovascular incident.
  • Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo
Freeze-dried placebo powder
Freeze-dried placebo powder
ACTIVE_COMPARATOR: Wild Blueberry powder
Freeze-dried whole fruit blueberry drink.
Freeze-dried whole fruit blueberry drink.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function
Time Frame: Change from baseline cognitive function at 2 hours post-consumption
Cognitive testing involves the participant conducting tasks administered on a tablet-style laptop. The participants will be conducting these tasks whilst cerebral blood flow measurements are taking place. The cognitive testing battery will consist of 4 tasks including a mood assessment (PANAS).
Change from baseline cognitive function at 2 hours post-consumption
Endothelial Function
Time Frame: Change from baseline endothelial function at 2 hours post-consumption
Flow mediated dilation (FMD)
Change from baseline endothelial function at 2 hours post-consumption

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cerebral blood flow (CBF)
Time Frame: Change of baseline cerebral blood flow at 2 hours post consumption
Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD)
Change of baseline cerebral blood flow at 2 hours post consumption
Blood pressure
Time Frame: Change from baseline systolic blood pressure at 2 hours post consumption
Automated clinical digital sphygmomanometer
Change from baseline systolic blood pressure at 2 hours post consumption

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma blueberry (poly)phenol metabolites
Time Frame: 2 hours
Measured by liquid chromotography- mass spectrometry (LC/MS)
2 hours
Urine (poly)phenol metabolites
Time Frame: Baseline and 12 weeks
24-hour urine samples
Baseline and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2018

Primary Completion (ACTUAL)

October 1, 2020

Study Completion (ACTUAL)

May 18, 2021

Study Registration Dates

First Submitted

April 6, 2018

First Submitted That Met QC Criteria

July 18, 2018

First Posted (ACTUAL)

July 19, 2018

Study Record Updates

Last Update Posted (ACTUAL)

May 19, 2021

Last Update Submitted That Met QC Criteria

May 18, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Placebo

Subscribe